nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.07.2012 | Original Paper

Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging

verfasst von: Tian Yang, Chuan Lin, Jian Zhai, Song Shi, Min Zhu, Nan Zhu, Jun-Hua Lu, Guang-Shun Yang, Meng-Chao Wu

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The BCLC staging classification has been widely endorsed to predict the prognosis of patients with HCC. However, its validity as a means of therapeutic instructions needs to be challenged. This study aimed to evaluate perioperative and long-term outcomes of surgical resection in patients with advanced hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer (BCLC) staging.

Methods

This study used a prospectively maintained database consisting of a consecutive series of 511 Chinese patients with advanced HCC who underwent surgical resection in a hepatobiliary surgical center from 2001 to 2007. Mortality, morbidity, long-term overall survival (OS) and disease-free survival (DFS) were evaluated.

Results

Hospital mortality was 2.3%, and overall morbidity was 31.3%. After a median follow-up period of 27.8 months (range, 0–112 months), the 1-, 3- and 5-year OS rate was 69.9, 41.2 and 30.5%, and the 1-, 3- and 5-year DFS rate was 48.2, 30.3 and 24.0%, respectively. The 1-, 3- and 5-year OS and DFS rates were significantly poorer in patients with vascular invasion and/or extrahepatic spread than those in patients without (both P < 0.001), and also poorer in patients with biliary invasion than those in patients without (both P < 0.05).

Conclusions

Surgical resection could be considered in part of patients with advanced HCC (BCLC stage C), with low mortality, acceptable morbidity and favorable survival benefits. These results imply that BCLC recommendations for treatment schedules of advanced HCC need to be re-evaluated.

Aldrighetti L, Pulitano C, Catena M et al (2009) Liver resection with portal vein thrombectomy for hepatocellular carcinoma with vascular invasion. Ann Surg Oncol 16(5):1254PubMedCrossRef

Bruix J, Llovet JM (2009) Major achievements in hepatocellular carcinoma. Lancet 373(9664):614–616PubMedCrossRef

Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRef

Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef

Chen MF, Jan YY, Jeng LB, Hwang TL, Wang CS, Chen SC (1994) Obstructive jaundice secondary to ruptured hepatocellular carcinoma into the common bile duct. Surgical experiences of 20 cases. Cancer 73(5):1335–1340PubMedCrossRef

Chen XP, Qiu FZ, Wu ZD et al (2006) Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 13(7):940–946PubMedCrossRef

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34PubMedCrossRef

Cillo U, Vitale A, Grigoletto F et al (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44(4):723–731PubMedCrossRef

Esaki M, Shimada K, Sano T, Sakamoto Y, Kosuge T, Ojima H (2005) Surgical results for hepatocellular carcinoma with bile duct invasion: a clinicopathologic comparison between macroscopic and microscopic tumor thrombus. J Surg Oncol 90(4):226–232PubMedCrossRef

Fukuda S, Okuda K, Imamura M, Imamura I, Eriguchi N, Aoyagi S (2002) Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 131(3):300–310PubMedCrossRef

Grieco A, Pompili M, Caminiti G et al (2005) Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54(3):411–418PubMedCrossRef

Ikenaga N, Chijiiwa K, Otani K, Ohuchida J, Uchiyama S, Kondo K (2009) Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg 13(3):492–497PubMedCrossRef

Inoue Y, Hasegawa K, Ishizawa T et al (2009) Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma. Surgery 145(1):9–19PubMedCrossRef

Kondo K, Chijiiwa K, Kai M et al (2009) Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg 13(6):1078–1083PubMedCrossRef

Konishi M, Ryu M, Kinoshita T, Inoue K (2001) Surgical treatment of hepatocellular carcinoma with direct removal of the tumor thrombus in the main portal vein. Hepatogastroenterology 48(41):1421–1424PubMed

Lau WY, Lai EC (2007) Salvage surgery following downstaging of unresectable hepatocellular carcinoma—a strategy to increase resectability. Ann Surg Oncol 14(12):3301–3309PubMedCrossRef

Lau WY, Lai EC (2008) Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 7(3):237–257PubMed

Lau WY, Leung TW, Leung KL et al (1994) Cytoreductive surgery for hepatocellular carcinoma. Surg Oncol 3(3):161–166PubMedCrossRef

Lau WY, Leung KL, Leung TW, Liew CT, Chan M, Li AK (1995) Resection of hepatocellular carcinoma with diaphragmatic invasion. Br J Surg 82(2):264–266PubMedCrossRef

Lau WY, Lai EC, Leung TW, Yu SC (2008) Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 247(1):43–48PubMedCrossRef

Le TYP, Hardwigsen J, Ananian P et al (2006) Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg 10(6):855–862CrossRef

Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48(4):1312–1327PubMedCrossRef

Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–338PubMedCrossRef

Llovet JM, Di BAM, Bruix J et al (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10):698–711PubMedCrossRef

Llovet JM, Ricci S, Mazzaferro V et al (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390PubMedCrossRef

Marrero JA (2006) Staging systems for hepatocellular carcinoma: should we all use the BCLC system. J Hepatol 44(4):630–632PubMedCrossRef

Marrero JA, Fontana RJ, Barrat A et al (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41(4):707–716PubMedCrossRef

Matsuda M, Suzuki T, Kono H, Fujii H (2007) Predictors of hepatic venous trunk invasion and prognostic factors in patients with hepatocellular carcinomas that had come into contact with the trunk of major hepatic veins. J Hepatobiliary Pancreat Surg 14(3):289–296PubMedCrossRef

Minagawa M, Makuuchi M, Takayama T, Ohtomo K (2001) Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 233(3):379–384PubMedCrossRef

Pawlik TM, Poon RT, Abdalla EK et al (2005) Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 137(4):403–410PubMedCrossRef

Peng SY, Wang JW, Liu YB et al (2004a) Hepatocellular carcinoma with bile duct thrombi: analysis of surgical treatment. Hepatogastroenterology 51(57):801–804PubMed

Peng SY, Wang JW, Liu YB et al (2004b) Surgical intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma. World J Surg 28(1):43–46PubMedCrossRef

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649PubMedCrossRef

Qin LX, Tang ZY (2003) Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol 9(3):385–391PubMed

Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23(13):2892–2899PubMedCrossRef

Wu MC (2004) Operative treatment of tumor thrombus in the portal vein. Zhonghua Yi Xue Za Zhi 84(1):1–2PubMed

Xiangji L, Weifeng T, Bin Y et al (2009) Surgery of hepatocellular carcinoma complicated with cancer thrombi in bile duct: efficacy for criteria for different therapy modalities. Langenbecks Arch Surg 394(6):1033–1039PubMedCrossRef

Yang T, Zhang J, Lu JH et al (2011) A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol 137(5):739–750PubMedCrossRef

Yeh CN, Jan YY, Lee WC, Chen MF (2004) Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi. World J Surg 28(5):471–475PubMedCrossRef

Titel: Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging
verfasst von: Tian Yang
Chuan Lin
Jian Zhai
Song Shi
Min Zhu
Nan Zhu
Jun-Hua Lu
Guang-Shun Yang
Meng-Chao Wu
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1188-0

Springer Medizin

Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging